Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 46

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 46
---
 sold in this offering will not change as a result of a change in the mix of the
Depositary Shares and Pre-Funded Warrants sold.

The Units have no standalone
rights and will not be certificated or issued as standalone securities. The Depositary Shares or Pre-Funded Warrants and Series L Warrants
comprising the Units are immediately separable and will be issued separately in this offering.

American Depositary Shares

Please see the sections titled
“Description of American Depositary Shares” and “Description of Share Capital” in this prospectus
for a description of the material terms of our American Depositary Shares and the underlying Ordinary Shares and our Articles of Association.

Pre-Funded Warrants and Series L Warrants

The following summary of certain terms and provisions of the Pre-Funded Warrants and Series L Warrants offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the form of Pre-Funded Warrant and the form of Series L Warrant, which will be filed as exhibits to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions set forth in the form of Series L Warrant and form of Pre-Funded Warrant.

Duration, Exercise Price and Form. The exercise price for the Pre-Funded Warrants is $0.0001 per Depositary Share. The Pre-Funded Warrants are exercisable
at any time after their original issuance until they are exercised in full. Each Series L Warrant will have an initial exercise price
equal to 100% of the public offering price per Unit. The Series L Warrants will be immediately exercisable upon issuance and will expire
five (5) years after the original issuance date. The exercise price and the number of Depositary Shares issuable upon exercise are subject
to adjustment in the event of share dividends, share splits, reorganizations, or similar events affecting our Ordinary Shares and the
exercise price.

We may be required to pay
certain amounts as liquidated damages as specified in the warrants in the event we do not deliver Depositary Shares upon exercise of
the warrants within the time periods specified in the warrants. No fractional Depositary Shares will be issued in connection with the
exercise of a warrant.

Cashless Exercise.
If, at the time a holder exercises its Series L Warrants, there is no effective registration statement registering, or the prospectus
contained therein is not available for an issuance of the shares underlying the Series L W